Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Poziotinib in EGFR or HER2 Mutant Advanced Solid Tumors

NCT03066206 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03066206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03066206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Poziotinib in EGFR or HER2 Mutant Advanced Solid Tumors
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
March 17, 2017
Completion date
February 16, 2026
Enrollment
93 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr exon 20 mutation, erbb2 gene mutation, recurrent lung non-small cell carcinoma, stage iv non-small cell lung cancer ajcc v7